JP2018504901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504901A5 JP2018504901A5 JP2017535417A JP2017535417A JP2018504901A5 JP 2018504901 A5 JP2018504901 A5 JP 2018504901A5 JP 2017535417 A JP2017535417 A JP 2017535417A JP 2017535417 A JP2017535417 A JP 2017535417A JP 2018504901 A5 JP2018504901 A5 JP 2018504901A5
- Authority
- JP
- Japan
- Prior art keywords
- cysteine
- receptor agonist
- acid
- receptor
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000018417 cysteine Nutrition 0.000 claims description 40
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 40
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 36
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 30
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 24
- 235000003704 aspartic acid Nutrition 0.000 claims description 24
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 24
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 22
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 22
- 235000013922 glutamic acid Nutrition 0.000 claims description 22
- 239000004220 glutamic acid Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 20
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 20
- 229940044601 receptor agonist Drugs 0.000 claims description 20
- 239000000018 receptor agonist Substances 0.000 claims description 20
- 235000014393 valine Nutrition 0.000 claims description 20
- 239000004474 valine Substances 0.000 claims description 20
- 239000004475 Arginine Substances 0.000 claims description 18
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 18
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 18
- 235000009697 arginine Nutrition 0.000 claims description 18
- 239000002464 receptor antagonist Substances 0.000 claims description 17
- 229940044551 receptor antagonist Drugs 0.000 claims description 17
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 16
- 239000004472 Lysine Substances 0.000 claims description 16
- 235000018977 lysine Nutrition 0.000 claims description 16
- 208000008589 Obesity Diseases 0.000 claims description 14
- 235000020824 obesity Nutrition 0.000 claims description 14
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 12
- 150000001413 amino acids Chemical group 0.000 claims description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 12
- 235000004554 glutamine Nutrition 0.000 claims description 12
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- 235000004400 serine Nutrition 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 8
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 8
- 101800001982 Cholecystokinin Proteins 0.000 claims description 8
- 102100025841 Cholecystokinin Human genes 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- 102400001132 Melanin-concentrating hormone Human genes 0.000 claims description 8
- 101800002739 Melanin-concentrating hormone Proteins 0.000 claims description 8
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 8
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 8
- 229940107137 cholecystokinin Drugs 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 230000001747 exhibiting effect Effects 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 235000005772 leucine Nutrition 0.000 claims description 8
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 8
- 208000013016 Hypoglycemia Diseases 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- QHSCIWIRXWFIGH-LURJTMIESA-N (2s)-2-amino-2-methylpentanedioic acid Chemical group OC(=O)[C@](N)(C)CCC(O)=O QHSCIWIRXWFIGH-LURJTMIESA-N 0.000 claims description 4
- 229940124035 Amylin receptor agonist Drugs 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 4
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 4
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 4
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 4
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 claims description 4
- 101800001586 Ghrelin Proteins 0.000 claims description 4
- 102000000393 Ghrelin Receptors Human genes 0.000 claims description 4
- 108010016122 Ghrelin Receptors Proteins 0.000 claims description 4
- 102400000442 Ghrelin-28 Human genes 0.000 claims description 4
- 102000051325 Glucagon Human genes 0.000 claims description 4
- 108060003199 Glucagon Proteins 0.000 claims description 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 229940122942 Leptin receptor agonist Drugs 0.000 claims description 4
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 claims description 4
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 claims description 4
- 108050006759 Pancreatic lipases Proteins 0.000 claims description 4
- 102000019280 Pancreatic lipases Human genes 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 claims description 4
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims description 4
- 229960004666 glucagon Drugs 0.000 claims description 4
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 229940116369 pancreatic lipase Drugs 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002485 serotonin 2C agonist Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- IMOBSLOLPCWZKQ-UHFFFAOYSA-N 2-(dimethylazaniumyl)-3-(1h-imidazol-5-yl)propanoate Chemical group CN(C)C(C(O)=O)CC1=CN=CN1 IMOBSLOLPCWZKQ-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 2
- 229930195711 D-Serine Natural products 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical group C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Chemical group CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 2
- 108010063919 Glucagon Receptors Proteins 0.000 claims description 2
- 102100040890 Glucagon receptor Human genes 0.000 claims description 2
- 239000004471 Glycine Chemical group 0.000 claims description 2
- 108010077895 Sarcosine Proteins 0.000 claims description 2
- 208000003874 Simpson-Golabi-Behmel syndrome Diseases 0.000 claims description 2
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical group OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 229960003638 dopamine Drugs 0.000 claims 2
- 230000009103 reabsorption Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140193800 | 2014-12-30 | ||
| KR10-2014-0193800 | 2014-12-30 | ||
| PCT/KR2015/014422 WO2016108586A1 (ko) | 2014-12-30 | 2015-12-30 | 안정성이 증가된 글루카곤 유도체 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144259A Division JP7079301B2 (ja) | 2014-12-30 | 2020-08-28 | 安定性が増加されたグルカゴン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504901A JP2018504901A (ja) | 2018-02-22 |
| JP2018504901A5 true JP2018504901A5 (OSRAM) | 2019-02-07 |
| JP6797122B2 JP6797122B2 (ja) | 2020-12-09 |
Family
ID=56284642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535417A Active JP6797122B2 (ja) | 2014-12-30 | 2015-12-30 | 安定性が増加されたグルカゴン誘導体 |
| JP2020144259A Active JP7079301B2 (ja) | 2014-12-30 | 2020-08-28 | 安定性が増加されたグルカゴン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144259A Active JP7079301B2 (ja) | 2014-12-30 | 2020-08-28 | 安定性が増加されたグルカゴン誘導体 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11135271B2 (OSRAM) |
| EP (2) | EP3575314B1 (OSRAM) |
| JP (2) | JP6797122B2 (OSRAM) |
| KR (1) | KR102291020B1 (OSRAM) |
| CN (1) | CN107636009B (OSRAM) |
| AR (1) | AR103322A1 (OSRAM) |
| AU (1) | AU2015372818A1 (OSRAM) |
| CA (1) | CA2972748A1 (OSRAM) |
| CL (1) | CL2017001718A1 (OSRAM) |
| CO (1) | CO2017006308A2 (OSRAM) |
| CR (1) | CR20170293A (OSRAM) |
| DO (1) | DOP2017000156A (OSRAM) |
| EA (1) | EA035527B1 (OSRAM) |
| EC (1) | ECSP17040923A (OSRAM) |
| ES (1) | ES2976562T3 (OSRAM) |
| GT (1) | GT201700150A (OSRAM) |
| HK (1) | HK1248713A1 (OSRAM) |
| IL (2) | IL253206B (OSRAM) |
| MA (1) | MA40709B1 (OSRAM) |
| MX (1) | MX2017008569A (OSRAM) |
| MY (1) | MY185334A (OSRAM) |
| PE (2) | PE20171154A1 (OSRAM) |
| PH (1) | PH12017501222B1 (OSRAM) |
| SG (1) | SG11201705376SA (OSRAM) |
| TN (1) | TN2017000271A1 (OSRAM) |
| TW (1) | TW201639878A (OSRAM) |
| UA (1) | UA126960C2 (OSRAM) |
| WO (1) | WO2016108586A1 (OSRAM) |
| ZA (1) | ZA201705015B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103322A1 (es) * | 2014-12-30 | 2017-05-03 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón con estabilidad mejorada |
| CR20180034A (es) * | 2015-06-30 | 2018-04-16 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo. |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| AU2016382394B2 (en) | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
| PE20190355A1 (es) * | 2016-06-29 | 2019-03-07 | Hanmi Pharm Ind Co Ltd | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo |
| KR102645064B1 (ko) | 2017-02-03 | 2024-03-08 | 한미약품 주식회사 | 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도 |
| AU2018388331B2 (en) * | 2017-12-22 | 2025-07-03 | Hanmi Pharm. Co., Ltd. | Therapeutic enzyme fusion protein having a novel structure and use thereof |
| US20210030847A1 (en) * | 2018-01-23 | 2021-02-04 | Xeris Pharmaceuticals, Inc. | Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon |
| KR20200078414A (ko) | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 인슐린 및 글루카곤을 포함하는 약학 조성물 |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| IL298396A (en) | 2020-05-22 | 2023-01-01 | Hanmi Pharm Ind Co Ltd | Liquid formulation of long-acting conjugate of glucagon derivative |
| AU2021308828A1 (en) | 2020-07-15 | 2023-02-23 | Hanmi Pharm. Co., Ltd. | Therapeutic use of glucagon derivative or conjugate thereof for liver disease |
| US20240197834A1 (en) | 2021-04-09 | 2024-06-20 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative |
| KR20230095666A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| BRPI0407936A (pt) | 2003-03-19 | 2006-02-21 | Lilly Co Eli | composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| BRPI0406606A (pt) | 2003-11-13 | 2005-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo |
| AU2007240313B2 (en) | 2006-04-20 | 2012-02-02 | Amgen Inc. | GLP-1 compounds |
| CA2674354A1 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| EA017849B1 (ru) | 2007-02-15 | 2013-03-29 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соагонисты глюкагоновых/glp-1-рецепторов |
| WO2008152403A1 (en) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
| JP5646848B2 (ja) | 2007-06-19 | 2014-12-24 | 株式会社糖鎖工学研究所 | 糖鎖付加ｇｌｐ−１ペプチド |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| EA020326B9 (ru) | 2008-06-17 | 2015-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения |
| US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| CN102459325B (zh) | 2009-06-16 | 2015-03-25 | 印第安纳大学科技研究有限公司 | 胃抑胜肽受体活化的胰高血糖素化合物 |
| PT2454282E (pt) | 2009-07-13 | 2015-06-23 | Zealand Pharma As | Análogos de glucagão acilados |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| BR112012018104A2 (pt) * | 2010-01-20 | 2017-10-17 | Zeland Pharma As | tratamento de doenças cardíacas |
| BR112012024379A2 (pt) * | 2010-03-26 | 2017-01-10 | Novo Nordisk As | "peptídeos glucagon, seu uso, bem como composição farmacêutica" |
| CN103179976A (zh) | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| US10471127B2 (en) | 2011-05-18 | 2019-11-12 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
| RU2739209C2 (ru) | 2011-06-10 | 2020-12-21 | Ханми Сайенс Ко., Лтд. | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения |
| SI2721062T1 (sl) * | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
| EP2729493B1 (en) | 2011-07-04 | 2020-06-10 | IP2IPO Innovations Limited | Novel compounds and their effects on feeding behaviour |
| US8859491B2 (en) * | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| KR20150039748A (ko) | 2012-06-21 | 2015-04-13 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체 활성을 나타내는 글루카곤의 유사체들 |
| JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| US9724420B2 (en) | 2012-11-06 | 2017-08-08 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| EP4047023A1 (en) | 2012-11-20 | 2022-08-24 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| KR102365582B1 (ko) | 2012-11-20 | 2022-02-18 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 약제 |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| RU2683039C2 (ru) * | 2013-04-18 | 2019-03-26 | Ново Нордиск А/С | Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения |
| EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| JP6657230B2 (ja) | 2014-09-24 | 2020-03-04 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | インクレチン−インスリンコンジュゲート |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| AR103322A1 (es) | 2014-12-30 | 2017-05-03 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón con estabilidad mejorada |
| CR20180034A (es) * | 2015-06-30 | 2018-04-16 | Hanmi Pharm Ind Co Ltd | Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo. |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| AU2016382394B2 (en) | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
-
2015
- 2015-12-30 AR ARP150104340A patent/AR103322A1/es unknown
- 2015-12-30 ES ES19172184T patent/ES2976562T3/es active Active
- 2015-12-30 UA UAA201707040A patent/UA126960C2/uk unknown
- 2015-12-30 SG SG11201705376SA patent/SG11201705376SA/en unknown
- 2015-12-30 AU AU2015372818A patent/AU2015372818A1/en not_active Abandoned
- 2015-12-30 MA MA40709A patent/MA40709B1/fr unknown
- 2015-12-30 CA CA2972748A patent/CA2972748A1/en active Pending
- 2015-12-30 TW TW104144427A patent/TW201639878A/zh unknown
- 2015-12-30 MX MX2017008569A patent/MX2017008569A/es unknown
- 2015-12-30 US US15/540,729 patent/US11135271B2/en active Active
- 2015-12-30 EA EA201791333A patent/EA035527B1/ru not_active IP Right Cessation
- 2015-12-30 KR KR1020150189532A patent/KR102291020B1/ko active Active
- 2015-12-30 EP EP19172184.4A patent/EP3575314B1/en active Active
- 2015-12-30 HK HK18104685.2A patent/HK1248713A1/en unknown
- 2015-12-30 TN TN2017000271A patent/TN2017000271A1/en unknown
- 2015-12-30 EP EP15875680.9A patent/EP3241841A4/en not_active Withdrawn
- 2015-12-30 PE PE2017001168A patent/PE20171154A1/es unknown
- 2015-12-30 PH PH1/2017/501222A patent/PH12017501222B1/en unknown
- 2015-12-30 CR CR20170293A patent/CR20170293A/es unknown
- 2015-12-30 PE PE2022001996A patent/PE20230304A1/es unknown
- 2015-12-30 MY MYPI2017000967A patent/MY185334A/en unknown
- 2015-12-30 WO PCT/KR2015/014422 patent/WO2016108586A1/ko not_active Ceased
- 2015-12-30 JP JP2017535417A patent/JP6797122B2/ja active Active
- 2015-12-30 CN CN201580077186.3A patent/CN107636009B/zh active Active
-
2017
- 2017-06-27 IL IL253206A patent/IL253206B/en unknown
- 2017-06-27 CO CONC2017/0006308A patent/CO2017006308A2/es unknown
- 2017-06-28 GT GT201700150A patent/GT201700150A/es unknown
- 2017-06-28 CL CL2017001718A patent/CL2017001718A1/es unknown
- 2017-06-28 EC ECIEPI201740923A patent/ECSP17040923A/es unknown
- 2017-06-29 DO DO2017000156A patent/DOP2017000156A/es unknown
- 2017-07-24 ZA ZA2017/05015A patent/ZA201705015B/en unknown
-
2020
- 2020-08-28 JP JP2020144259A patent/JP7079301B2/ja active Active
-
2021
- 2021-03-09 IL IL281375A patent/IL281375B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504901A5 (OSRAM) | ||
| RU2017105866A (ru) | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения | |
| JP2021138740A (ja) | Ｇｉｐアゴニスト化合物及び方法 | |
| JP6797122B2 (ja) | 安定性が増加されたグルカゴン誘導体 | |
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| NZ768446A (en) | Novel glp-1 analogues | |
| PE20190355A1 (es) | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo | |
| JP2010502734A5 (OSRAM) | ||
| JP2006514104A5 (OSRAM) | ||
| JP2010515686A5 (OSRAM) | ||
| TW201119668A (en) | Peptidic GLP-2 agonists | |
| TWI353250B (en) | Glp-1 pharmaceutical compositions | |
| JP2005530732A5 (OSRAM) | ||
| HRP20230385T1 (hr) | Kombinirana terapija sa cnp agonistima s kontroliranim oslobađanjem | |
| JP2019533722A5 (OSRAM) | ||
| JP2004537581A5 (OSRAM) | ||
| JP2010536714A5 (OSRAM) | ||
| JP2004521123A5 (OSRAM) | ||
| JP2018505153A5 (OSRAM) | ||
| JP2011517675A5 (OSRAM) | ||
| CN101983068A (zh) | N末端和c末端取代的新型人gh-rh拮抗类似物 | |
| RU2018145945A (ru) | Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма | |
| JP2019522046A5 (OSRAM) | ||
| JP2014515751A5 (OSRAM) | ||
| JP2009507077A5 (OSRAM) |